Article Information
History
- January 5, 2024.
Article Versions
- Version 1 (September 12, 2023 - 12:39).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Hugh Claridge1,2,*,
- Claire A. Price1,2,
- Rofique Ali3,
- Elizabeth A. Cooke2,
- Simon de Lusignan4,
- Adam Harvey-Sullivan3,5,
- Catherine Hodges6,
- Natalia Khalaf7,
- Dean O’Callaghan3,
- Ali Stunt8,
- Spencer A. Thomas2,
- Joanna Thomson6 and
- Agnieszka Lemanska1,2
- 1School of Health Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
- 2National Physical Laboratory, Teddington, UK
- 3Tower Hamlets Network 1 Primary Care Network, London, UK
- 4Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
- 5Centre for Primary Care, Wolfson Institute of Population Health, Queen Mary University of London
- 6Surrey and Sussex Cancer Alliance, Guildford, UK
- 7Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
- 8Pancreatic Cancer Action, Hampshire, UK
- ↵*Correspondence to: Hugh Claridge, h.claridge{at}surrey.ac.uk
Posted January 05, 2024.
Determining the feasibility of calculating pancreatic cancer risk scores for people with new-onset diabetes in primary care (DEFEND PRIME): study protocol
